• Company
  • News
  • Investors
  • Contacts
  • Careers
polypeptide-logopolypeptide-logologo-mobilepolypeptide-logo
  • Services
    • GMP Compliance
    • Pre-GMP development
    • Production
    • Quality Assurance
    • Quality control
    • Regulatory Support
  • Commercial Manufacturing
    • Commercial products at PolyPeptide
    • Late stage development
    • Process development and optimization
    • Capacity and Capabilities
  • Custom R&D
    • Custom Research Grade Peptides
    • Radiolabeled peptide
  • Generic peptides
  • Oligos
  • Services
    • GMP Compliance
    • Pre-GMP development
    • Production
    • Quality Assurance
    • Quality control
    • Regulatory Support
  • Commercial Manufacturing
    • Commercial products at PolyPeptide
    • Late stage development
    • Process development and optimization
    • Capacity and Capabilities
  • Custom R&D
    • Custom Research Grade Peptides
    • Radiolabeled peptide
  • Generic peptides
  • Oligos
✕
  • Home
  • News
  • Business news
  • New in-silico development tools support more efficient process design

New in-silico development tools support more efficient process design

8 December 2020
Business news
Pic graphic

The Polypeptide Group has developed a set of tools using Ypso-Proxima® software. They help make the most efficient choices at an early stage.

The field of Solid Phase Peptide Synthesis (SPPS) has boomed over the last few decades. But many companies are still relying on procedures used in the laboratory to achieve large-scale production. This has proven to be inefficient and not cost-effective. Not surprisingly, the overall quest to produce high-quality peptides at lower costs while meeting customers’ expectations for issues like cutting solvent consumption (and reducing environmental impact) without affecting the product quality has intensified.

Pharmaceutical manufacturers expect their CMDOs to deliver an efficient, yet robust and cost-optimized process for producing the final product. But a trial-and-error strategy that pushes the development of an optimal process later is not the most effective approach.

As part of an innovation program called “Advanced Peptide Synthesis,” the Polypeptide Group has developed a set of tools using Ypso-Proxima® software that helps its development chemists make the most efficient choices at an early stage. These tools include:

  • A predictive toolbox to preliminarily assess new peptides using a database with decades of accumulated knowledge
  • Simulation tools that represent complex peptide chemistry mechanisms and allow optimization of the process in silico

A chemist’s predictive toolbox

The structured database goes beyond basic information about molecular weight, hydrophobicity plot and the evolution of net charge with respect to pH. It aggregates information about peptide sequence edition, predictions of charges vs pH, mass spectra, conformation potential, solubility of peptides, impurity profile, and solvent consumption for downstream processes, which supports better selection of raw materials, and estimations of coupling times for given target peptide yield and purity. Confidence in the predictive results is increasing over time as more and more cases are fed to the database, including complex peptides with exotic motifs and exotic building blocks.

SPPS simulation tool

The simulation tool gives chemists answers to questions such as: what are the rate- determining steps within the set of reactions involved in a peptide synthesis, how to boost the reaction kinetics, and how to optimize the volume of solvent used? The simulation tools are based on results from measuring the evolution of a system over time and developing numerical models that are able to represent the reaction mechanisms.

Using these new in-silico development toolboxes, peptide chemists will be a step closer to being “right the first time” in their iterative development strategy.

See publication in Chemistry Today, issue September/October 2020 with Olivier Ludemann-Hombourger, Global Director Innovation & Technology, PolyPeptide Group, Strasbourg, France

 

Back to news

Related posts

24 April 2025

Alzinova Advances ALZ-101 Development with Drug Substance Release, Paving the Way for Phase 2 Clinical Trial


Read more
27 August 2024

Vinnova grant awarded to joint project between PolyPeptide and Red Glead Discovery for developing a more sustainable manufacturing method for a GLP-1 agonist.


Read more
8 May 2023

PolyPeptide launches new “Innovation Lab”


Read more

Polypeptide Group

INFO

COMPANY
LEADERSHIP
CONTACTS
CAREERS

NEWS

LATEST NEWS
SIGN UP FOR NEWS
EVENTS

SOCIALS

LINKEDIN
YOUTUBE
© Confidentiality 2025 PolyPeptide Group • Cookie Policy • Sitemap • Privacy policy
    • Company
    • News
    • Investors
    • Contacts
    • Careers